Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
Harrison SA, Abdurakhmanov D, Shiffman ML, Bakulin I, Mazur W, Rodriguez-Torres M, Silva GF, Cheinquer H, Messinger D, Connell EV, McKenna M, Tatsch F, Reddy KR; PROGRESS Investigators. Harrison SA, et al. Among authors: abdurakhmanov d. J Clin Gastroenterol. 2013 Mar;47(3):271-9. doi: 10.1097/MCG.0b013e31826102eb. J Clin Gastroenterol. 2013. PMID: 22951527
Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
Reddy KR, Shiffman ML, Rodriguez-Torres M, Cheinquer H, Abdurakhmanov D, Bakulin I, Morozov V, Silva GF, Geyvandova N, Stanciu C, Rabbia M, McKenna M, Thommes JA, Harrison SA; PROGRESS Study Investigators. Reddy KR, et al. Among authors: abdurakhmanov d. Gastroenterology. 2010 Dec;139(6):1972-83. doi: 10.1053/j.gastro.2010.08.051. Epub 2010 Sep 30. Gastroenterology. 2010. PMID: 20816836 Clinical Trial.
Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.
Colombo M, Fernández I, Abdurakhmanov D, Ferreira PA, Strasser SI, Urbanek P, Moreno C, Streinu-Cercel A, Verheyen A, Iraqi W, DeMasi R, Hill A, Läuffer JM, Lonjon-Domanec I, Wedemeyer H. Colombo M, et al. Among authors: abdurakhmanov d. Gut. 2014 Jul;63(7):1150-8. doi: 10.1136/gutjnl-2013-305667. Epub 2013 Nov 7. Gut. 2014. PMID: 24201995 Free PMC article. Clinical Trial.
Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.
Lepida A, Colombo M, Fernandez I, Abdurakhmanov D, Ferreira PA, Strasser SI, Urbanek P, Mangia A, Calleja JL, Iraqi W, DeMasi R, Lonjon-Domanec I, Moreno C, Wedemeyer H. Lepida A, et al. Among authors: abdurakhmanov d. PLoS One. 2015 Sep 23;10(9):e0138503. doi: 10.1371/journal.pone.0138503. eCollection 2015. PLoS One. 2015. PMID: 26398503 Free PMC article. Clinical Trial.
New nomenclature for fatty liver disease: Problems of localization in the regions and the position of Russian Scientific Liver Society.
Raikhelson K, Okovityi S, Abdurakhmanov D; Joint position statement of Russian Scientific Liver Society (RSLS). Raikhelson K, et al. Among authors: abdurakhmanov d. J Hepatol. 2024 Oct 23:S0168-8278(24)02644-8. doi: 10.1016/j.jhep.2024.10.023. Online ahead of print. J Hepatol. 2024. PMID: 39454691 No abstract available.
Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials.
Buti M, Lim YS, Chan HLY, Agarwal K, Marcellin P, Brunetto MR, Chuang WL, Janssen HLA, Fung SK, Izumi N, Jablkowski MS, Abdurakhmanov D, Abramov F, Wang H, Botros I, Yee LJ, Mateo R, Flaherty JF, Osinusi A, Pan CQ, Shalimar X, Seto WK, Gane EJ. Buti M, et al. Among authors: abdurakhmanov d. Aliment Pharmacol Ther. 2024 Dec;60(11-12):1573-1586. doi: 10.1111/apt.18278. Epub 2024 Sep 27. Aliment Pharmacol Ther. 2024. PMID: 39327857 Free PMC article. Clinical Trial.
Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV.
Mateo R, Xu S, Shornikov A, Yazdi T, Liu Y, May L, Han B, Han D, Martin R, Manhas S, Richards C, Marceau C, Aeschbacher T, Chang S, Manuilov D, Hollnberger J, Urban S, Asselah T, Abdurakhmanov D, Lampertico P, Maiorova E, Mo H. Mateo R, et al. Among authors: abdurakhmanov d. JHEP Rep. 2023 Aug 22;5(11):100893. doi: 10.1016/j.jhepr.2023.100893. eCollection 2023 Nov. JHEP Rep. 2023. PMID: 37929228 Free PMC article.
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks.
Fung SK, Pan CQ, Wong GL, Seto WK, Ahn SH, Chen CY, Hann HL, Jablkowski MS, Kim YJ, Yurdaydin C, Peng CY, Nguyen T, Yatsuhashi H, Flaherty JF, Yee LJ, Abramov F, Wang H, Abdurakhmanov D, Lim YS, Buti M. Fung SK, et al. Among authors: abdurakhmanov d. Aliment Pharmacol Ther. 2024 Jan;59(2):217-229. doi: 10.1111/apt.17764. Epub 2023 Oct 31. Aliment Pharmacol Ther. 2024. PMID: 37905449
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.
Chan HLY, Buti M, Lim YS, Agarwal K, Marcellin P, Brunetto M, Chuang WL, Janssen HLA, Fung S, Izumi N, Abdurakhmanov D, Jabłkowski M, Celen MK, Ma X, Caruntu F, Flaherty JF, Abramov F, Wang H, Camus G, Osinusi A, Pan CQ, Shalimar, Seto WK, Gane E; GS-US-320-0110 and GS-US-320-0108 investigators. Chan HLY, et al. Among authors: abdurakhmanov d. Am J Gastroenterol. 2024 Mar 1;119(3):486-496. doi: 10.14309/ajg.0000000000002468. Epub 2023 Aug 9. Am J Gastroenterol. 2024. PMID: 37561058 Free PMC article. Clinical Trial.
49 results